Detalles de la búsqueda
1.
Randomized, double-blind, multicenter study to evaluate efficacy, safety, tolerability, and immunogenicity between AVT04 and the reference product ustekinumab in patients with moderate-to-severe chronic plaque psoriasis.
Expert Opin Biol Ther
; 23(8): 759-771, 2023.
Artículo
en Inglés
| MEDLINE | ID: mdl-37435850
2.
Assessing the Interchangeability of AVT02 and Humira® in Participants with ModeratetoSevere Chronic Plaque Psoriasis: Pharmacokinetics, Efficacy, Safety, and Immunogenicity Results from a Multicenter, Double-Blind, Randomized, Parallel-Group Study.
BioDrugs
; 37(4): 551-567, 2023 Jul.
Artículo
en Inglés
| MEDLINE | ID: mdl-37204631
3.
A randomized, double-blind, 3-arm, parallel study assessing the pharmacokinetics, safety, tolerability and immunogenicity of AVT04, an ustekinumab candidate biosimilar, in healthy adults.
Expert Opin Investig Drugs
; 32(5): 417-427, 2023 May.
Artículo
en Inglés
| MEDLINE | ID: mdl-37212315
Resultados
1 -
3
de 3
1
Próxima >
>>